OOOPDS
Taiwan Main Orthopaedic Biotechnology Co., Ltd. · Decision date Sep 15, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 09/15/2026 for OOOPDS, a 510(k) submitted by Taiwan Main Orthopaedic Biotechnology Co., Ltd. of Taichung, Taiwan. The submission, K254214, was received 12/29/2025 and reviewed under regulation 892.2050 in the radiology specialty, with classification product code LLZ and the device classification name System, Image Processing, Radiological. SESE in this context means the device was cleared for marketing; it is not a PMA approval.
The record identifies the submission as a traditional 510(k) that was not reviewed by a third party, not a combination product, and without an authorized predetermined change control plan. The public record does not state which predicate device was used, what the substantial-equivalence basis was, or what the device's indications for use are; the summary field is empty. No clinical performance, imaging accuracy or patient-outcome data appear in the available text, so none can be reported here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 15, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254214
- Regulatory pathway
- 510(k) premarket notification
- Product code
- LLZ
- Decision code
- SESE
- Decision date
- Sep 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Image Processing, Radiological.
- Product code
- LLZ
- FDA device class
- 2
FDA decision timeline
K254214 received
Application receipt date recorded by FDA.
K254214 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LLZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
3D Anatomical ModelK262132 | The Jacobs Institute | 510(k) clearance | Nov 5, 2026 | FDA |
LiLi DICOM Viewer (LiLi )K260454 | Elevate Imaging, Inc. | 510(k) clearance | Nov 4, 2026 | FDA |
| Canon Medical Informatics, Inc. | 510(k) clearance | Oct 29, 2026 | FDA | |
MIM KineticIDK261763 | Mim Software, Inc. | 510(k) clearance | Oct 26, 2026 | FDA |
PV-iCurve ProK261531 | Perception Vision Medical Technology Co., Ltd. | 510(k) clearance | Oct 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Taiwan Main Orthopaedic Biotechnology Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Taichung
Sources and methodology
- Original FDA record: K254214
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


